AUSTIN, Texas and TOKYO, Oct. 3, 2025 /PRNewswire/ -- According to DataM Intelligence, the Active Pharmaceutical Ingredients Market Size reached US$ 238.7 Billion in 2024, up from US$ 224.7 Billion in ...

Dublin, Oct. 02, 2025 (GLOBE NEWSWIRE) -- The "Europe Active Pharmaceutical Ingredients Market Size, Share & Trends Analysis Report by Synthesis, by Manufacturer, by Type (Generic APIs, Innovative ...

Dublin, Dec. 03, 2025 (GLOBE NEWSWIRE) -- The "United States Active Pharmaceutical Ingredients (APIs) Market - Growth, Trends & Forecast 2025-2033" report has been added to ResearchAndMarkets.com's ...

The traditional APIs segment accounted for the largest share in 2024, whereas the HPAPI segment is expected to grow at the fastest CAGR over the forecast period. The HPAPI segment is further segmented ...

Protein aggregation and active principle ingredients (API) stability are factors that ultimately impact both the usability and quality of many biopharmaceutical products, especially injectables. The ...

Europe has anticipated expanding significantly in the global active pharmaceutical ingredient (API) market and will probably carry on the same fashion over the forecast period. This is attributable to ...

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Specialty Active Pharmaceutical Ingredients (API) Market: Global Industry Analysis and Opportunity Assessment, ...

DUBLIN--(BUSINESS WIRE)--The "United States Active Pharmaceutical Ingredients Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2024" report has been added to ...

The Global Active Pharmaceutical Ingredients (API) Market is valued at USD 209.80 Billion in 2024 and is projected to reach a value of USD 445.7 Billion by 2035 at a CAGR (Compound Annual Growth Rate) ...

PARIS, Feb 24 (Reuters) - Sanofi said on Monday it intended to create a standalone company dedicated to the production of active pharmaceutical ingredients. Active pharmaceutical ingredients (API) ...

TEL AVIV, Israel--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the appointment of Dr. R. Ananthanarayanan (Ananth) as CEO of its Teva Active ...